Falcon-HD
Study of SKY-0515 for Safety, Efficacy, and Pharmacodynamics in Participants With Huntington's Disease
Phase 2/3 study testing SKY-0515 to see whether it can lower harmful huntingtin protein levels.
Active, not recruitingPhase 2 / Phase 3DrugClinicalTrials.govTreatment trial
Recruiting in: Adelaide, Auckland, Caulfield South +8 more (Australia, New Zealand)
Sponsor: Skyhawk Therapeutics, Inc.
Preparing a short plain-English summary.